索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]李伟华,胡鹏,毕树雄.色素沉着绒毛结节性滑膜炎的研究进展[J].国际骨科学杂志,2021,01:40-44.
点击复制

色素沉着绒毛结节性滑膜炎的研究进展(PDF)

《国际骨科学杂志》[ISSN:1673-7083/CN:31-1952/R]

期数:
2021年01期
页码:
40-44
栏目:
综述
出版日期:
2021-02-10

文章信息/Info

Title:
-
作者:
李伟华; 胡鹏; 毕树雄
030032 太原, 山西医科大学附属白求恩医院骨科
Author(s):
-
关键词:
色素沉着绒毛结节性滑膜炎;  关节镜手术;  放射治疗;  靶向治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-7083.2021.01.010
文献标识码:
-
摘要:
色素沉着绒毛结节性滑膜炎(PVNS)是由滑膜异常增生形成的良性疾病,多由染色体易位引起,具有炎症和肿瘤双重特征。PVNS有局限型和弥漫型两种类型,具有局部侵袭性,临床表现主要为关节疼痛、肿胀和活动受限。PVNS通常以MRI检查作为最有价值的辅助检查手段,但其最终确诊仍有赖于组织病理检查。PVNS的主要治疗方式是通过手术切除病变滑膜,而放射治疗、靶向治疗等辅助治疗的有效性和安全性尚需进一步论证。该文就PVNS的研究进展作一综述。
Abstract:
-

参考文献/References

[1] Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors[J]. Acta Orthop, 2017, 88(6): 688-694.
[2] Daoud J, Aouad D, Hassan Y, et al. Localized pigmented villonodular synovitis of the posterior knee compartment with popliteal vessel compression: a case report of arthroscopic resection using only anterior knee portals[J]. Case Rep Orthop, 2018, 2018: 7532358.
[3] Zhao L, Zhou K, Hua Y, et al. Multifocal pigmented villonodular synovitis in a child: a case report[J]. Medicine(Baltimore), 2016, 95(33): e4572.
[4] Ma XM, Xia CY, Fu PL, et al. Unusual cases of pigmented villonodular synovitis after arthroplasty[J]. Int J Clin Exp Med, 2014, 7(4): 1150-1154.
[5] West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells[J]. Proc Natl Acad Sci U S A, 2006, 103(3): 690-695.
[6] Burton TM, Ye X, Parker ED, et al. Burden of illness associated with tenosynovial giant cell tumors[J]. Clin Ther, 2018, 40(4): 593-602.
[7] Tsuda Y, Hirata M, Katayama K, et al. Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations[J]. Int J Cancer, 2019, 145(12): 3276-3284.
[8] Ho J, Peters T, Dickson BC, et al. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors[J]. Genes Chromosomes Cancer, 2020, 59(2): 96-105.
[9] Sistla R, J.V.S V, Afroz T. Malignant pigmented villonodular synovitis: a rare entity[J]. J Orthop Case Rep, 2014, 4(4): 9-11.
[10] Alexiev BA, Tumer Y, Yang GY. Malignant tenosynovial giant cell tumor with CDKN2A/B genomic alteration: a histological, immunohistochemical, and molecular study[J]. Hum Pathol, 2017, 63: 144-148.
[11] Staals EL, Ferrari S, Donati DM, et al. Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives[J]. Eur J Cancer, 2016, 63: 34-40.
[12] Mollon B, Lee A, Busse JW, et al. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis[J]. Bone Joint J, 2015, 97B(4): 550-557.
[13] Palmerini E, Staals EL, Maki RG, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors[J]. Eur J Cancer, 2015, 51(2): 210-217.
[14] Patel KH, Gikas PD, Pollock RC, et al. Pigmented villonodular synovitis of the knee: a retrospective analysis of 214 cases at a UK tertiary referral centre[J]. Knee, 2017, 24(4): 808-815.
[15] Mastboom MJL, Staals EL, Verspoor FGM, et al. Surgical treatment of localized-type tenosynovial giant cell tumors of large joints: a study based on a multicenter-pooled database of 31 international sarcoma centers[J]. J Bone Joint Surg Am, 2019, 101(14): 1309-1318.
[16] Mollon B, Griffin AM, Ferguson PC, et al. Combined arthroscopic and open synovectomy for diffuse pigmented villonodular synovitis of the knee[J]. Knee Surg Sports Traumatol Arthrosc, 2016, 24(1): 260-266.
[17] Mastboom MJL, Palmerini E, Verspoor FGM, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study[J]. Lancet Oncol, 2019, 20(6): 877-886.
[18] Casp AJ, Browne JA, Durig NE, et al. Complications after total knee arthroplasty in patients with pigmented villonodular synovitis[J]. J Arthroplasty, 2019, 34(1): 36-39.
[19] Houdek MT, Scorianz M, Wyles CC, et al. Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis[J]. Knee, 2017, 24(4): 851-855.
[20] Iakovou I, Symeonidis P, Kotrotsios D, et al. Radiosynoviorthesis after surgery in the treatment of patients with ankle pigmented villonodular synovitis: a case series[J]. J Clin Med, 2020, 9(2): 597.
[21] Gortzak Y, Vitenberg M, Frenkel Rutenberg T, et al. Inconclusive benefit of adjuvant 90Yttrium hydroxyapatite to radiosynovectomy for diffuse-type tenosynovial giant-cell tumour of the knee[J]. Bone Joint J, 2018, 100-B(7): 984-988.
[22] Dürr HR, Capellen CF, Klein A, et al. The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee[J]. Arch Orthop Trauma Surg, 2019, 139(5): 623-627.
[23] Stephan SR, Shallop B, Lackman R, et al. Pigmented villonodular synovitis: a comprehensive review and proposed treatment algorithm[J]. JBJS Rev, 2016, 4(7): 01874474-201607000-00005.
[24] Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study[J]. Lancet Oncol, 2015, 16(8): 949-956.
[25] Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2018, 19(5): 639-648.
[26] Verspoor FGM, Mastboom MJL, Hannink G, et al. Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor[J]. Sci Rep, 2019, 9(1): 14551.
[27] Giustini N, Bernthal NM, Bukata SV, et al. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib(PLX3397)and review of the literature[J]. Clin Sarcoma Res, 2018, 8: 14.
[28] Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour(ENLIVEN): a randomised phase 3 trial[J]. Lancet, 2019, 394(10197): 478-487.
[29] NCCN. NCCN clinical practice guidelines in oncology: soft tissue sarcoma[EB/OL]. [2020-05-18]. https://www.nccn.org/patients/guidelines/content/PDF/sarcoma-patient.pdf.
[30] Cook NS, Landskroner K, Shah B, et al. Identification of patient needs and preferences in pigmented villonodular synovitis(PVNS)using a qualitative online bulletin board study[J]. Adv Ther, 2020, 37(6): 2813-2828.
(收稿:2020-06-22)
(本文编辑:富饶)

备注/Memo

备注/Memo:
通信作者: 毕树雄 E-mail: Bishuxiong168@sohu.com
更新日期/Last Update: 2021-02-10